Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Roche And Synta Ink Collaboration
by Rick Mullin
January 12, 2009
| A version of this story appeared in
Volume 87, Issue 2
Synta Pharmaceuticals and Roche have formed an alliance to develop small-molecule drugs targeting a novel family of ion channels critical to immune cell function known as calcium-release-activated calcium-modulator channels. Under the terms of the agreement, Roche will fund research to be conducted by Synta during an initial two-year research period and receive worldwide rights to develop and commercialize certain products. Synta will receive $25 million in up-front license fees and research support.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter